Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Modest, S. Stintzing, R. Laubender, J. Neumann, A. Jung, C. Giessen, M. Haas, Philipp Aubele, C. Schulz, S. Boeck, H. Stemmler, T. Kirchner, V. Heinemann (2011)Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status
Anti-Cancer Drugs, 22
H. Hurwitz, J. Yi, William Ince, W. Novotny, O. Rosen (2009)The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
The oncologist, 14 1
A. Jawhari, A. Buda, Michelle Jenkins, Khurram Shehzad, C. Sarraf, M. Noda, M. Farthing, M. Pignatelli, J. Adams (2003)Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro.
The American journal of pathology, 162 1
H. Bouzourène, P. Gervaz, J. Cerottini, J. Benhattar, P. Chaubert, E. Saraga, S. Pampallona, F. Bosman, J. Givel (2000)p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
European journal of cancer, 36 8
Charles Chan, L. Jankova, C. Fung, C. Clarke, G. Robertson, P. Chapuis, L. Bokey, B. Lin, O. Dent, S. Clarke (2010)Fascin Expression Predicts Survival After Potentially Curative Resection of Node-positive Colon Cancer
The American Journal of Surgical Pathology, 34
J. Mendelsohn, J. Baselga (2003)Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 14
M. Esteller, S. González, R. Risques, E. Marcuello, R. Mangues, J. Germà, J. Herman, G. Capellá, M. Peinado (2001)K-ras and p16 aberrations confer poor prognosis in human colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 2
A. Russo, V. Bazan, V. Agnese, V. Rodolico, N. Gebbia (2005)Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
Annals of oncology : official journal of the European Society for Medical Oncology, 16 Suppl 4
Y. Hashimoto, Dae-Joong Kim, J. Adams (2011)The roles of fascins in health and disease
The Journal of Pathology, 224
S. Oh, Y. Kim, K. Suh, O. Paek, H. Moon (2012)Prognostic impact of fascin-1 expression is more significant in advanced colorectal cancer.
The Journal of surgical research, 172 1
V. Heinemann, S. Stintzing, T. Kirchner, S. Boeck, A. Jung (2009)Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Cancer treatment reviews, 35 3
G. Puppa, P. Maisonneuve, A. Sonzogni, M. Masullo, A. Chiappa, M. Valerio, M. Zampino, I. Franceschetti, P. Capelli, M. Chilosi, F. Menestrina, G. Viale, G. Pelosi (2007)Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma
British Journal of Cancer, 96
N. Hynes, H. Lane (2005)ERBB receptors and cancer: the complexity of targeted inhibitors
Nature Reviews Cancer, 5
Y. Hashimoto, M. Skacel, I. Lavery, A. Mukherjee, G. Casey, J. Adams (2006)Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas
BMC Cancer, 6
B. Dix, P. Robbins, R. Soong, Deborah Jenner, A. House, B. Iacopetta (1994)The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short‐term prognostic indicators of survival
International Journal of Cancer, 59
M El Zouhairi, A Charabaty, MJ Pishvaian (2011)Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents
Gastrointest Cancer Res, 4
J. Baselga, C. Arteaga (2005)Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
I. Zlobec, A. Lugli (2008)Prognostic and predictive factors in colorectal cancer
Journal of Clinical Pathology, 61
Nina Kureishy, Vasileia Sapountzi, Soren Prag, N. Anilkumar, Josephine Adams, Josephine Adams (2002)Fascins, and their roles in cell structure and function.
BioEssays : news and reviews in molecular, cellular and developmental biology, 24 4
H. Andreyev, A. Norman, P. Clarke, D. Cunningham, J. Oates (1998)Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.
Journal of the National Cancer Institute, 90 9
Christina Wu, A. Charabaty, M. Pishvaian, J. Marshall (2010)Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New Agents
Current Colorectal Cancer Reports, 6
J. Neumann, E. Zeindl‐Eberhart, T. Kirchner, A. Jung (2009)Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Pathology, research and practice, 205 12
J. Krieken, A. Jung, T. Kirchner, F. Carneiro, R. Seruca, F. Bosman, P. Quirke, J. Fléjou, T. Hansen, G. Hertogh, P. Jares, C. Langner, G. Hoefler, M. Ligtenberg, D. Tiniakos, S. Tejpar, G. Bevilacqua, A. Ensari (2008)KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
Virchows Archiv, 453
Henrik Petrowsky, Henrik Petrowsky, Isrid Sturm, O. Graubitz, D. Kooby, E. Staib-Sebler, C. Gog, C. Köhne, Timo Hillebrand, Peter Daniel, Peter Daniel, Yuman Fong, Matthias Lorenz (2001)Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 27 1
S. Tórtola, E. Marcuello, I. González, G. Reyes, R. Arribas, G. Aiza, F. Sancho, M. Peinado, G. Capellá (1999)p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 5
Colorectal adenocarcinoma (CRC) is a major cause of death. Fascin expression in CRCs was proved to be related with higher metastatic rates and poor prognosis, while metastatic patients with only wild type K-RAS gene are the candidates of recent molecularly targeted anti-epidermal growth factor receptor (EGFR) therapies. This study is designed to investigate the correlation between the fascin expression status and the K-RAS mutational status of CRCs in order to assess the availability rate of anti-EGFR therapies for patients with fascin-expressing CRCs. Immunohistochemical expression of fascin and mutational status of K-RAS were investigated in the archival materials of randomly selected 50 metastatic colorectal carcinoma patients. Strength of fascin expression and tumor percentage stained with fascin were scored semi quantitatively. c.34 > C (p.G12R), c.35 g > C (p.G12C), c.34G > A (p.G12S), c.35G > A (p.G12D), c.35G > T (p.G12V), c.35G > C (p.G12A), and c.38G > A (p.G13.D) mutations in K-RAS gene were studied by using RT-PCR. In immunohistochemical evaluation, 32 of the 50 cases stained positive with fascin, while 21 were positive for K-RAS mutations in codon 12 (10 patients) or in codon 13 (3 patients). The correlation between the positivity of fascin and the presence of K-RAS mutations, the strength of fascin staining and the presence of K-RAS mutations, and the tumor cell percentage stained with fascin and the presence of K-RAS mutations were found statistically significant. The results of this study suggest that patients with fascin-expressing CRCs have a greater tendency to carry an activating K-RAS mutation which will prevent them from taking targeted anti-EGFR therapies. Larger series are needed to confirm these results.
Targeted Oncology – Springer Journals
Published: Apr 16, 2013
Access the full text.
Sign up today, get DeepDyve free for 14 days.